Japanese Encephalitis (JE) Vaccine Market to Reach $1,128.4 Million by 2035

Japanese Encephalitis (JE) Vaccine market was valued at $650.1 million in 2025 and is expected to reach $1,128.4 million by 2035, registering a CAGR of 5.8% during the forecast period from 2026 to 2035. The market is expanding due to the persistent disease burden across endemic regions, combined with the increasing integration of vaccination into national immunization programs. The absence of specific antiviral treatment has positioned vaccination as the primary preventive strategy, leading governments to prioritize large-scale immunization campaigns. Continued transmission across the Asia-Pacific and emerging detections in new geographies are reinforcing the need for a sustained vaccine supply. In addition, public health agencies are strengthening surveillance and response systems, which are improving diagnosis and vaccine demand planning. This alignment between disease risk and policy-driven immunization is directly supporting consistent market growth across both public and private distribution channels.

Browse the full report description of “Japanese Encephalitis (JE) Vaccine Market Size, Share & Trends Analysis Report by Type (Inactivated Vaccines, Recombinant Vaccines, and Live Attenuated Vaccines), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce, and Government/Public Health Programs), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/japanese-encephalitis-je-vaccine-market

Rising Case Incidence and Mortality Data Supporting Market Expansion

• Over 3 billion people live in JE-endemic regions across 24 countries, indicating a large at-risk population base.
• Japanese encephalitis causes approximately 68,000 clinical cases annually, maintaining a significant global disease burden.
• The disease has a case fatality rate of up to 30%, highlighting the critical need for preventive vaccination.
• Around 30–50% of survivors develop long-term neurological complications, increasing the importance of early immunization.
• In 2025, India reported over 224 confirmed cases across 11 states, reflecting continued endemic transmission.
• Countries such as Nepal reported a rise to 164 cases in 2025 from 86 in 2024, indicating resurgence trends in certain regions.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Type
  • Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Biological E. Ltd., Bharat Biotech International Ltd., Chengdu Institute of Biological Products Co., Ltd., Sanofi Pasteur, Valneva SE, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Japanese Encephalitis (JE) Vaccine Market Report Segment

By Type

• Inactivated Vaccines
• Recombinant Vaccines
• Live Attenuated Vaccines

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce
• Government/Public Health Programs

Global Japanese Encephalitis (JE) Vaccine Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/japanese-encephalitis-je-vaccine-market